George Poste, Director, The Biodesign Institute
Just Announced: George Poste, Director, The Biodesign Institute to Present at R&D Directions’ 4th Annual Drug Development Summit
NEWTOWN, Pa., November 17, 2006 –
R&D Directions is excited to announce a keynote presentation by George Poste, D.V.M., Ph.D., D.Sc., F.R.S., Director, The Biodesign Institute at the Drug Development Summit on January 24, 2007 in Phoenix, AZ. Dr. Poste’s presentation will examine technology’s effect on the business structure of R&D, which new technologies are effective and emerging technologies on the horizon.
Dr. Poste was appointed in May 2003 as the Director of The Biodesign Institute at Arizona State University. In June of 2006, he was awarded the Albert Einstein Award by the Global Business Leadership Council in recognition of outstanding achievement in advancing human health worldwide. He was named ”Scientist of the Year” by R&D Magazine in 2004 in tribute to his incredible past accomplishments and recognition of his leadership in establishing the Biodesign Institute as a confluence of leading edge technologies.
Dr. Poste’s 38-year career has encompassed roles in academia, industry and government, with expertise in disciplines as diverse as molecular biology, pharmaceutical development, and biosecurity. A highly-sought speaker, Poste is engaged by groups as diverse as public health officials, NATO, the U.S. Department of Defense, and the pharmaceutical and biotech industries.
From 1992 to 1999, Dr. Poste was Chief Science and Technology Officer and President of Research & Development for one of the largest pharmaceutical companies in the world, SmithKline Beecham. In an industry where bringing a single drug to market makes careers, Poste oversaw registration of 31 drug, vaccine and diagnostic products. In addition to his academic post, he serves as Chief Executive of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare.
He is a Fellow of the Royal Society, and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution at Stanford University and is a member of the Council for Foreign Relations. In the wake of the 9-11 terrorist attacks, Poste’s expertise was tapped extensively to aid national security. He served as chairman of the task force on bioterrorism for the U.S. Department of Defense, a role he completed in May 2004, and currently serves as a member of the Threat Reduction Advisory Committee for the Defense Threat Reduction Agency.
Dr. Poste will be joined by a distinguished faculty of key industry leaders at the Drug Development Summit. Join us to honor R&D Directions' Top Ten Pipeline Winners, interact with key industry leaders, and network with R&D executives. Hear in-depth knowledge and actionable plans for transforming your R&D operations at the summit. Additional topics to be addressed at the Summit are as follows:
• Cost-Effectiveness through Structural Change
• New Approaches to Adaptive Trial Design
• Avoiding Costly Late-Stage Failures
• Predictive Models to Reduce Attrition
• Post-Marketing Studies
For more information about the Drug Development Summit visit us online at www.drugdevelopmentsummit.com or call 800-437-9997.
Drug Development Summit
Transforming R&D: Experience-Tested Strategies for Increasing Productivity and Innovation
January 21-24, 2007 ? Phoenix, AZ
NEWTOWN, Pa., November 17, 2006 –
R&D Directions is excited to announce a keynote presentation by George Poste, D.V.M., Ph.D., D.Sc., F.R.S., Director, The Biodesign Institute at the Drug Development Summit on January 24, 2007 in Phoenix, AZ. Dr. Poste’s presentation will examine technology’s effect on the business structure of R&D, which new technologies are effective and emerging technologies on the horizon.
Dr. Poste was appointed in May 2003 as the Director of The Biodesign Institute at Arizona State University. In June of 2006, he was awarded the Albert Einstein Award by the Global Business Leadership Council in recognition of outstanding achievement in advancing human health worldwide. He was named ”Scientist of the Year” by R&D Magazine in 2004 in tribute to his incredible past accomplishments and recognition of his leadership in establishing the Biodesign Institute as a confluence of leading edge technologies.
Dr. Poste’s 38-year career has encompassed roles in academia, industry and government, with expertise in disciplines as diverse as molecular biology, pharmaceutical development, and biosecurity. A highly-sought speaker, Poste is engaged by groups as diverse as public health officials, NATO, the U.S. Department of Defense, and the pharmaceutical and biotech industries.
From 1992 to 1999, Dr. Poste was Chief Science and Technology Officer and President of Research & Development for one of the largest pharmaceutical companies in the world, SmithKline Beecham. In an industry where bringing a single drug to market makes careers, Poste oversaw registration of 31 drug, vaccine and diagnostic products. In addition to his academic post, he serves as Chief Executive of Health Technology Networks, a consulting company that specializes in the application of genomic technologies and computing in healthcare.
He is a Fellow of the Royal Society, and the UK Academy of Medicine, a Distinguished Fellow at the Hoover Institution at Stanford University and is a member of the Council for Foreign Relations. In the wake of the 9-11 terrorist attacks, Poste’s expertise was tapped extensively to aid national security. He served as chairman of the task force on bioterrorism for the U.S. Department of Defense, a role he completed in May 2004, and currently serves as a member of the Threat Reduction Advisory Committee for the Defense Threat Reduction Agency.
Dr. Poste will be joined by a distinguished faculty of key industry leaders at the Drug Development Summit. Join us to honor R&D Directions' Top Ten Pipeline Winners, interact with key industry leaders, and network with R&D executives. Hear in-depth knowledge and actionable plans for transforming your R&D operations at the summit. Additional topics to be addressed at the Summit are as follows:
• Cost-Effectiveness through Structural Change
• New Approaches to Adaptive Trial Design
• Avoiding Costly Late-Stage Failures
• Predictive Models to Reduce Attrition
• Post-Marketing Studies
For more information about the Drug Development Summit visit us online at www.drugdevelopmentsummit.com or call 800-437-9997.
Drug Development Summit
Transforming R&D: Experience-Tested Strategies for Increasing Productivity and Innovation
January 21-24, 2007 ? Phoenix, AZ
posted by Famous Quotations - George Poste, Director, The Biodesign Institute
0 Comments:
Post a Comment
Links to this post:
Create a Link
<< Home